Floatz logo

Crpa1A2

Hepatocellular Carcinoma (HCC)

Corregene Biotechnology Co., LtdPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

520 Active assets in the Hepatocellular Carcinoma (HCC) cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Crpa1A2 is also rated in:

lung cancerDormant
CC
Indicative ·
43 / 100
View asset →
esophageal cancerDormant
CC
Indicative ·
41 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →